MXPA05008352A - Metodos para la purificacion de conjugados estables de radioyodo. - Google Patents
Metodos para la purificacion de conjugados estables de radioyodo.Info
- Publication number
- MXPA05008352A MXPA05008352A MXPA05008352A MXPA05008352A MXPA05008352A MX PA05008352 A MXPA05008352 A MX PA05008352A MX PA05008352 A MXPA05008352 A MX PA05008352A MX PA05008352 A MXPA05008352 A MX PA05008352A MX PA05008352 A MXPA05008352 A MX PA05008352A
- Authority
- MX
- Mexico
- Prior art keywords
- purification
- methods
- anion
- exchange resin
- solution
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 title abstract 2
- 238000000746 purification Methods 0.000 title 1
- 239000003957 anion exchange resin Substances 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000008685 targeting Effects 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/04—Disaccharides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/359,276 US7521531B2 (en) | 1996-08-28 | 2003-02-06 | Methods for the purification of stable radioiodine conjugates |
| PCT/US2004/003305 WO2004071571A1 (en) | 2003-02-06 | 2004-02-04 | Methods for the purification of stable radioiodine conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05008352A true MXPA05008352A (es) | 2005-11-04 |
Family
ID=32867920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05008352A MXPA05008352A (es) | 2003-02-06 | 2004-02-04 | Metodos para la purificacion de conjugados estables de radioyodo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7521531B2 (https=) |
| EP (1) | EP1592476B1 (https=) |
| JP (1) | JP4732331B2 (https=) |
| KR (1) | KR101022145B1 (https=) |
| CN (1) | CN1768266A (https=) |
| AT (1) | ATE359511T1 (https=) |
| CA (1) | CA2515088C (https=) |
| DE (1) | DE602004005826T2 (https=) |
| IL (1) | IL170030A (https=) |
| MX (1) | MXPA05008352A (https=) |
| WO (1) | WO2004071571A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7312318B2 (en) * | 2002-03-01 | 2007-12-25 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
| US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US7172751B2 (en) * | 2003-06-13 | 2007-02-06 | Immunomedics, Inc. | D-amino acid peptides |
| EP1638989B1 (en) * | 2003-06-25 | 2008-07-30 | Peregrine Pharmaceuticals, Inc. | Method and apparatus for continuous large-scale radiolabeling of proteins |
| US7318925B2 (en) | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
| CN1838968A (zh) | 2003-08-08 | 2006-09-27 | 艾伯吉尼斯公司 | 针对甲状旁腺激素(pth)之抗体和其用途 |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| GB0520529D0 (en) | 2005-10-10 | 2005-11-16 | Ge Healthcare Ltd | Automated radiolabelling method |
| US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
| HRP20140240T4 (hr) | 2005-11-30 | 2017-02-24 | Abbvie Inc. | Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US8524239B2 (en) | 2010-07-09 | 2013-09-03 | The United States of America as represented by the Secrectary, Department of Health and Human Services | Photosensitizing antibody-fluorophore conjugates |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| CA2841120C (en) * | 2011-07-11 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-ir700 conjugates for photodynamic therapy |
| US8927732B2 (en) | 2012-03-30 | 2015-01-06 | General Electric Company | Biotin stannane for HPLC-free radioiodination |
| KR101426422B1 (ko) | 2012-05-10 | 2014-08-06 | 한국원자력연구원 | 안질환 또는 암 치료용 아이오딘 씨드의 제조방법 및 이에 의하여 제조되는 아이오딘 씨드 |
| AU2014225381B2 (en) | 2013-03-08 | 2018-05-17 | University Of Southern California Usc Stevens | Vinylsulfone-based 18f-labeling compositions and methods and uses thereof |
| US10830678B2 (en) | 2014-08-08 | 2020-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Photo-controlled removal of targets in vitro and in vivo |
| CN121270700A (zh) | 2015-08-07 | 2026-01-06 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗癌症的针对抑制细胞的近红外光免疫疗法(nir-pit) |
| ES2889904T3 (es) | 2015-08-18 | 2022-01-14 | Rakuten Medical Inc | Conjugados de colorante de ftalocianina y su almacenamiento |
| US11154620B2 (en) | 2015-08-18 | 2021-10-26 | Rakuten Medical, Inc. | Compositions, combinations and related methods for photoimmunotherapy |
| US10799597B2 (en) | 2017-04-03 | 2020-10-13 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO169947C (no) | 1981-10-27 | 1992-08-26 | Hybritech Inc | Fremgangsmaate for fremstilling av et monoklonalt antistoff til et tumorassosiert antigen |
| SE466403B (sv) * | 1988-03-24 | 1992-02-10 | Kurt G I Nilsson | Saett att syntetisera oligosackarider |
| FR2652004B1 (fr) | 1989-09-21 | 1994-10-28 | Immunotech Partners | Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques. |
| US5273738A (en) | 1990-03-03 | 1993-12-28 | Fred Hutchinson Cancer Research Center | Radiation delivery to lymphoid and marrow tissues |
| ATE125270T1 (de) | 1990-12-21 | 1995-08-15 | Pliva Pharm & Chem Works | Tert-butyloxycarbonyl-l-tyrosyl- peptidoglycanmonomer und deren 125 i-markiertes derivat, deren herstellung und verwendung. |
| US5554745A (en) | 1992-05-14 | 1996-09-10 | National Starch And Chemical Investment Holding Corporation | Aldehyde cationic derivatives of galactose containing polysaccharides used as paper strength additives |
| CA2189051C (en) | 1994-04-29 | 2008-06-17 | M. Jules Mattes | Composition for delivery of toxic radioisotopes to the cell nucleus and use |
| US5672335A (en) | 1994-11-30 | 1997-09-30 | Schering Aktiengesellschaft | Use of metal complexes as liver and gallbladder X-ray diagnostic agents |
| ATE194143T1 (de) | 1996-08-28 | 2000-07-15 | Immunomedics Inc | Stabile radioiodium-konjugate und verfahren zu deren herstellung |
| US6558669B1 (en) | 1996-08-28 | 2003-05-06 | Immunomedics, Inc. | Stable radioiodine conjugates and methods for their synthesis |
| US6663866B1 (en) | 1996-08-28 | 2003-12-16 | Immunomedics, Inc. | Stable radioiodine conjugates and methods for their synthesis |
| EP1507562B1 (en) * | 2002-05-29 | 2010-03-24 | Immunomedics, Inc. | Compositions for radioimmunotherapy of brain |
-
2003
- 2003-02-06 US US10/359,276 patent/US7521531B2/en not_active Expired - Fee Related
-
2004
- 2004-02-04 JP JP2006503348A patent/JP4732331B2/ja not_active Expired - Fee Related
- 2004-02-04 KR KR1020057014399A patent/KR101022145B1/ko not_active Expired - Fee Related
- 2004-02-04 MX MXPA05008352A patent/MXPA05008352A/es not_active Application Discontinuation
- 2004-02-04 WO PCT/US2004/003305 patent/WO2004071571A1/en not_active Ceased
- 2004-02-04 DE DE602004005826T patent/DE602004005826T2/de not_active Expired - Lifetime
- 2004-02-04 EP EP04708243A patent/EP1592476B1/en not_active Expired - Lifetime
- 2004-02-04 CA CA2515088A patent/CA2515088C/en not_active Expired - Fee Related
- 2004-02-04 CN CNA2004800091734A patent/CN1768266A/zh active Pending
- 2004-02-04 AT AT04708243T patent/ATE359511T1/de active
-
2005
- 2005-08-02 IL IL170030A patent/IL170030A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1592476A1 (en) | 2005-11-09 |
| US7521531B2 (en) | 2009-04-21 |
| KR101022145B1 (ko) | 2011-03-17 |
| US20030220470A1 (en) | 2003-11-27 |
| JP2006517230A (ja) | 2006-07-20 |
| ATE359511T1 (de) | 2007-05-15 |
| CN1768266A (zh) | 2006-05-03 |
| DE602004005826D1 (de) | 2007-05-24 |
| WO2004071571A1 (en) | 2004-08-26 |
| IL170030A (en) | 2011-06-30 |
| EP1592476B1 (en) | 2007-04-11 |
| JP4732331B2 (ja) | 2011-07-27 |
| KR20050103219A (ko) | 2005-10-27 |
| DE602004005826T2 (de) | 2008-01-10 |
| CA2515088A1 (en) | 2004-08-26 |
| CA2515088C (en) | 2011-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05008352A (es) | Metodos para la purificacion de conjugados estables de radioyodo. | |
| CY1121151T1 (el) | Αντισωματα ως προς opgl | |
| EA200001169A1 (ru) | Специфично связывающиеся молекулы для сцинтиграфии, содержащие их конъюгаты и терапевтический способ лечения ангиогенеза | |
| NZ716641A (en) | Process for preparing maytansinoid antibody conjugates | |
| EA200100224A1 (ru) | Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20 | |
| TW200510459A (en) | RG1 antibodies and uses thereof | |
| NZ595450A (en) | Antibodies to M-CSF | |
| BR0314814A (pt) | Variantes otimizadas de fc e métodos para sua geração | |
| DK0710228T3 (da) | Hydraziner med N3S-konfiguration som radionuclidchelatorer | |
| CY1117729T1 (el) | Μεθοδοι για την παρασκευη κυτταροτοξικων συζευγματων μεϋτανσινοειδων και παραγοντων δεσμευσης κυτταρου | |
| DK1629011T3 (da) | Humane anti-humane-DC3-bindingsmolekyler | |
| EA200501286A1 (ru) | МОЛЕКУЛЫ АНТИТЕЛ СО СПЕЦИФИЧНОСТЬЮ К ЧЕЛОВЕЧЕСКОМУ IL-1β | |
| EP1505990A4 (en) | METHOD FOR THE TREATMENT OF HEPATITIS | |
| MY154009A (en) | Anti-alpha v beta 6 antibodies | |
| MXPA05008222A (es) | Metodos y composiciones para administrar agentes terapeuticos y de diagnostico. | |
| EP1708751A4 (en) | METHOD OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGEN EXPOSED ON APOPTOTIC TUMOR CELLS | |
| DE60130256D1 (de) | Naphthalinderivate, die sich an den ep4?rezeptor binden | |
| IL163902A0 (en) | Antibodies against cancer antigen tmeff2 and uses thereof | |
| DK1404377T3 (da) | Forbedrede chelatorkonjugater | |
| ATE178053T1 (de) | N2s2-chelatoren des hydrazino-typs | |
| WO2003028640A3 (en) | In vivo panning for ligands to radiation-induced molecules | |
| WO2003104425A3 (en) | NEW STABLE ANTI-CD22 ANTIBODIES | |
| ATE517340T1 (de) | Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren | |
| EA200401366A1 (ru) | Способы лечения некротизирующего энтероколита | |
| DE69434384D1 (de) | Metalkomplexbildner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |